Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders


This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and
tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in
combination with ruxolitinib in participants with MF who are transfusion-dependent or
presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and
Mohan, Sanjay

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Multiple Cancer Types

This is a global, Phase 1/3, multicenter, open-label study to evaluate the efficacy and
safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-nave myelofibrosis
(MF) participants. The study will be conducted in two phases: Phase 1 and Phase 3. Phase 1
(enrollment completed) was an open-label evaluation of the safety and recommended dose (RD)
of selinexor in combination with ruxolitinib and included a dose escalation using a standard
3+3 design (Phase 1a) and a dose expansion part (Phase 1b). In Phase 3, JAKi treatment-nave
MF participants are enrolled in 2:1 ratio to receive the combination therapy of selinexor +
ruxolitinib or the combination of placebo + ruxolitinib.
Hematologic, Phase I
Mohan, Sanjay

To learn more about any of our clinical
trials, call 615-936-8422.